Bionomics IPO Presentation Deck slide image

Bionomics IPO Presentation Deck

Offering Summary Issuer Ticker / Exchange Gross Proceeds Option to Purchase ADSS Use of Proceeds Lock-Up Period Active Bookrunners Expected Pricing Bionomics PTSD = Post-Traumatic Stress Disorder Represents ADS ratio of 180 Bionomics Limited BNOX / Nasdaq Global Market -$25.0 million (1,620,000 ADS, 100% primary, excluding over-allotment) -$3.75 million (15% of the offering ADSS) To advance BNC210 into a Phase 2 trial for the acute treatment of Social Anxiety Disorder (SAD), including the initiation and completion of the planned Phase 2 PREVAIL clinical trial H The continued development of BNC210 for the treatment of PTSD, including completion of the ongoing Phase 2b ATTUNE clinical trial E The completion of chemistry, manufacturing and controls, long term safety and non-clinical pharmacology studies necessary to support Phase 3 pivotal trials of BNC210 for the treatment of SAD and PTSD Working capital and other research and development and general corporate purposes 180 days for the Company, directors, executive officers and certain shareholders Evercore ISI, William Blair Week of December 13, 2021 3
View entire presentation